Loading…
← CockpitCompetitor Analysis › TGTX TG Therapeutics, Inc.Open in the cockpit ↗

TG Therapeutics, Inc.TGTXCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Biotech selling Briumvi, a B-cell-depleting antibody infusion for multiple sclerosis.

Momentum leader 96
Mkt cap
$9.99B
US dollars, full cap
Free float
93%
of shares outstanding
$/day
$133M
20-day average traded
Fwd P/E
25.2×
forward earnings
ROIC−WACC
+4.7 pp
WACC 13.9%
Hurdle
-384 pp
Req g minus delivered
Next earnings
104 days
2 Mar 2027
Close · USD$66.12
1D+5.4%
1W+0.6%
1M+21.2%
3M+30.8%
6M+66.3%
YTD+121.8%
1Y+115.4%
ATR %4.7%
Beta0.68
52w lowhigh2.8% off high

What TG Therapeutics does

Biotech selling Briumvi, a B-cell-depleting antibody infusion for multiple sclerosis.

Nearly all revenue is Briumvi sold in the US to infusion centres, clinics and hospitals through specialty distributors and reimbursed by insurers. After withdrawing its earlier lymphoma drug Ukoniq in 2022, it is a one-product company.

Products and services

  • Briumvi (multiple sclerosis)

Customers

  • Neurologists
  • Health systems
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • Multiple sclerosis / autoimmune

What could go right

  • Briumvi share gains from convenient infusion schedule
  • International expansion of Briumvi

What could go wrong

  • Single-product revenue concentration
  • Intense competition from established MS antibody franchises

Moat: narrow (IP / patents, installed base). Differentiated shorter-infusion anti-CD20 antibody competing for share in a crowded MS market.

Headquarters: New York, New York, United States · Founded: 1993 · Employees: 399

Named competitors

TG Therapeutics at a glance

Size TG Therapeutics (TGTX) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $9.99B, the 766th largest of 3,085 United States companies the cockpit tracks. Shares closed at $66.12 on 18 Nov 2026.

Performance Over six months the shares gained 66.3%, against +7.3% for the median peer and -2.2% for the United States market (cap-weighted) — 2nd highest of 21 in its peer set.

Growth Revenue grew 68.8% over the last twelve months (peer median +13.3%); the operating margin is 21.5% (peer median 16.8%).

Valuation It trades at 25.2× forward earnings against a peer median of 33.1× (6th cheapest of 16).

Price implies For today's price to make sense, revenue must grow about 43% a year for seven years (Req g). Recent delivered growth is +427%, so the hurdle is -384 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.7 points above its cost of capital (13.9% WACC).

Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012515021 May 202621 Aug 202618 Nov 2026TGTX 169Peer median 109
Six months, rebased to 100: TG Therapeutics against the median of its 20 peers (local-currency closes).

TG Therapeutics financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$898M$616M$329M$234M$2.79M
Revenue growth—+87%+41%+8,290%—
Gross profit$743M$516M$290M$219M$2.00M
EBITDA$194M$125M$42.2M$21.1M-$192M
Net income$106M$447M$23.4M$12.7M-$198M
Free cash flow$85.6M-$25.0M-$40.6M-$31.4M-$176M
Capital expenditure$693,000$214,000$45,000$0$14,000
Total debt$754M$254M$254M$111M$83.1M

Quarterly statements and history in the cockpit →

TG Therapeutics competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%+60%0%+20%300759SYREMDGLHLUN-ARGENMANKIND600436PRAX4151RECPTGX2607RYTM1177DRREDDYGLENMARKALK-BALKSZYDUSLIFE2196TGTX6-month return →1-month return →
Up and to the right = strong over both horizons. TG Therapeutics is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%+150%0×500×1,000×1,500×300759MDGLRGEN600436PTGX2607TGTXRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. TG Therapeutics is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%+400%0%200%400%HLUN-ARGENMANKIND4151TGTXGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. TG Therapeutics is the large dot.

TG Therapeutics competitors and peer comparison

Head to head with its named competitors (TGTX vs RO.SW vs NOVN.SW vs BIIB)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
TG Therapeutics TGTX$9.99B+66%+69%21%25.2×43.0%
Roche RO.SW$381B+21%-1%31%19.9×1.7%
Novartis NOVN.SW$285B+11%-4%30%17.5×1.6%
Biogen BIIB$37.2B+34%+2%17%17.1×10.1%
Sanofi SAN.PA$114B+13%+15%27%9.7×-4.8%
Bristol Myers Squibb BMY$122B+3%+4%33%9.2×-13.1%
Merck KGaA MRK.DE$71.3B+16%+1%19%17.4×7.4%

How TG Therapeutics compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

TG Therapeutics against its 20 peers (data as of 18 Nov 2026)
MeasureTGTXPeer medianRank in peer set
1-month return+21.2%+5.6%3rd highest of 21
6-month return+66.3%+7.3%2nd highest of 21
Distance from 52-week high-2.8%-11.2%6th highest of 21
Revenue growth (TTM)+68.8%+13.3%3rd highest of 20
Operating margin21.5%16.8%7th highest of 19
Forward P/E25.2×33.1×6th cheapest of 16
Growth the price implies (Req g, 7 yrs)43.0%18.7%2nd most demanding of 15
Growth delivered (Del g)+426.7%+9.3%highest of 15
Hurdle (Req g minus delivered)-383.7 pp+9.0 ppleast demanding of 15
ROIC minus cost of capital+4.7 pp+1.3 pp7th highest of 19
EV / EBITDA52.9×22.6×2nd most expensive of 14
Net debt / EBITDA1.3×0.0×4th most indebted of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
TG Therapeutics TGTXUnited States$9.99B+66%+69%21%25.2×43.0%+426.7%
Pharmaron Beijing 300759.SZChina$9.90B+52%+18%14%36.8×n/an/a
Spyre Therapeutics SYREUnited States$9.64B+41%n/an/an/an/an/a
Madrigal Pharmaceuticals MDGLUnited States$9.25B-22%+93%-11%81.5×n/an/a
H. Lundbeck A/S HLUN-A.CODenmark$9.16B+69%+9%26%n/a-6.6%+6.6%
Repligen RGENUnited States$11.0B+55%+14%9%71.0×56.9%+15.0%
Mankind Pharma MANKIND.NSIndia$11.6B+5%+13%21%44.4×28.6%+18.1%
Zhangzhou Pientzehuang Pharmaceutical 600436.SSChina$11.6B-4%-19%19%40.7×24.9%+6.8%
Praxis Precision Medicines PRAXUnited States$8.53B-9%-100%n/an/an/an/a
Kyowa Kirin 4151.TJapan$8.43B+9%+10%24%16.4×-4.7%+9.3%
Recordati REC.MIItaly$12.0B+3%+8%30%16.6×1.1%+12.6%
Protagonist Therapeutics PTGXUnited States$8.30B+26%+164%59%1,532.5×17.5%+10.0%
Shanghai Pharmaceuticals 2607.HKHong Kong$8.25B-7%+9%3%6.3×-9.7%+7.4%
Rhythm Pharmaceuticals RYTMUnited States$8.25B+31%+61%-67%n/an/an/a
Sbp 1177.HKHong Kong$12.2B+5%+15%30%17.5×-5.7%+5.4%
Dr. Reddy's Laboratories DRREDDY.NSIndia$12.5B+5%-4%9%32.0×30.7%+12.1%
Glenmark Pharmaceuticals GLENMARK.NSIndia$7.98B+10%0%17%33.1×27.3%+9.4%
ALK-abello A/S ALK-B.CODenmark$7.94B-8%+16%26%34.8×7.3%+12.6%
Alkermes Public ALKSUnited States$7.87B+27%+15%5%n/a32.5%+7.3%
Zydus Lifesciences ZYDUSLIFE.NSIndia$12.8B+18%+24%17%30.0×n/an/a
Shanghai Fosun Pharmaceutical (Group) 2196.HKHong Kong$7.74B-15%+10%6%9.0×19.9%+5.8%

Questions

Who are TG Therapeutics's main competitors?
Named competitors: Roche (Ocrevus) (RO.SW), Novartis (Kesimpta) (NOVN.SW), Biogen (BIIB), Sanofi (SAN.PA), Bristol-Myers Squibb (BMY), Merck KGaA (MRK.DE). The cockpit's measured peer set (industry) also includes Pharmaron Beijing (300759.SZ), Spyre Therapeutics (SYRE), Madrigal Pharmaceuticals (MDGL), H. Lundbeck A/S (HLUN-A.CO), Repligen (RGEN), Mankind Pharma (MANKIND.NS).
Is TG Therapeutics expensive compared with its peers?
On forward p/e it trades at 25.2× against a peer median of 33.1×, 6th cheapest of 16 in its peer set. For today's price to make sense, revenue must grow about 43% a year for seven years (Req g). Recent delivered growth is +427%, so the hurdle is -384 pp: the price already allows for a slowdown.
How has TG Therapeutics stock performed?
Over six months to 18 Nov 2026 the shares returned +66.3% against +7.3% for the median peer; over one year +115.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.